Amount : | 1 mg |
Purification : | Purity: ≥99% |
Content : | liquid (1 mg/ml) |
Storage condition : | Store the product at 4°C for short term and at -20°C for long-term storage. The product is stable for 2 years at -20°C. |
Alternative Name : | Polyinosinic-polycytidylic acid, potassium salt (poly (I:C)) |
MW: High molecular weight (>1.5kb).
Toll-like receptor (TLR) 3 is an endosomal TLR that mediates immune responses against viral infections upon activation by its ligand double-stranded RNA, a replication intermediate of most viruses. TLR3 is expressed widely in the body and activates both the innate and adaptive immune systems. Toll-like receptor 3 (TLR3), melanoma differentiation-associated gene 5 (MDA5), and retinoic acid-inducible gene-I (RIG-I), all sensors of double-stranded RNA (dsRNA) are potent inducers of antiviral activity. dsRNA sensor activation -e.g. by poly (I:C)- induces pro-inflammatory TNF-α and antiviral IFN-β, but can also enhance the expression of pro-apoptotic proteins. Recently, poly (I:C)-induced cell death recently gained considerable attention as a tool to study the 'Ripoptosome' or 'Necrosome' complex, a novel intracellular signaling complex, thought to induce regulated necrosis, also called 'Necroptosis'.
There are currently no product reviews Write a review on this product! |
Customers who purchased this product also purchasedPam3CSK4
Imiquimod, TLR7 ligand (4-Amin...
E-64d
Camostat (mesylate)
Glecaprevir
Paritaprevir
Simeprevir (sodium salt)
Danoprevir
Grazoprevir
Asunaprevir
Boceprevir
BCMA Blocking Peptide
Langerin Stable Cell Line
mB7-H4 Stable Cell Line
Pam3CSK4
Imiquimod, TLR7 ligand (4-Amin...
E-64d
Camostat (mesylate)
Glecaprevir
Paritaprevir
Simeprevir (sodium salt)
Danoprevir
Grazoprevir
Asunaprevir
Boceprevir
BCMA Blocking Peptide
Langerin Stable Cell Line
mB7-H4 Stable Cell Line
Most viewed Products
Recombinant Human Thioredoxin-Like ...
Monoclonal antibody to Human PD-L1 ...
Monoclonal Antibody to Human IL-1be...
Monoclonal Antibody to Caspase-3 (P...
Polyclonal Antibody to Beta actin
Monoclonal Antibody to GAPDH (Clone...
Monoclonal antibody to B7-H4 (Clone...
Polyclonal Antibody to Beta Tubulin
NF-kB Leeporter™ Luciferase Repor...
Peroxidase conjugated Goat anti Mou...
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
《血管紧张素转换酶抑制剂在心血管病中应用的中国专家共识》.PDF(242.69k)
1、测定酶比活力:底物需要过量么?测定时间多长?是否可以加入过量的底物,然后测定3min吸光度的增加值,从吸光度的变化值计算比活力。
2、在酶抑制剂筛选的过程中,是否需要保证底物过量?还是要水浴一定时间让反应完全?我看到文献说用终浓度为0.1μmol/mL的底物,终浓度为45U/ml的酶,我想问,假设总体积为1ml,那么终浓度为45U/ml的酶岂不是每分钟能转化4.8μmol的底物?那么0.1μmol/mL的底物不就几秒钟就反应完了?那么怎么测定初速度?
1.对于抑制剂筛选工作(求ic50)是不是体系内酶与底物的量(底物应该是过量的)对实验结果影响不大。
2.如果要求算Km值,是不是需要知道反应产物的绝对量。反应时间文献上都是5分钟,反应速度就用反应产物量除以反应时间即可。
3.酶是进口分装的,规格5U,一次用不完,用PBS稀释后如何保存
谢谢
2、可逆抑制剂:包括
a、竞争性抑制剂,抑制剂与底物竞争性结合酶反应中心,使Km增大,而Vmax不变 b、非竞争性抑制剂,酶与抑制剂结合后还能与底物结合,但活性降低,使Vmax减小,而Km不变
c、反竞争性抑制剂,酶只能与底物结合后才能与抑制剂结合,Vmax与Km都减小
可逆抑制剂可用透析等方法除去,使酶恢复作用
暂无品牌问答